Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBCLN-010 and PBCLN-014 in Allo-HCT
NCT06102213Phase 2Terminated
- Sponsor
- Prolacta Bioscience
- Start
- Sep 2023
- Primary completion
- Aug 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Bifidobacterium longum subsp. infantis in hematologic malignancy (3 arms), sponsored by Prolacta Bioscience. Primary endpoints: Incidence and severity of safety and tolerability measures assessed through adverse events, serious adverse events, and adverse events of special interest, Rate of gut engraftment of B. infantis at 180 days and 1 more. Started Sep 2023; status: terminated.
02
Drugs
Bifidobacterium longum subsp. infantis
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT06102213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06102213.